Liver‐Intestine/Multivisceral Perspective: Indications, Patient Selection, and Allocation Policy
Richard S. Mangus – 6 November 2019
Microbiome Modulation in Liver Disease
Eamonn M.M. Quigley – 6 November 2019
Transplantation for Acute‐on‐Chronic Liver Failure
Tiffany Wu, Vinay Sundaram – 6 November 2019
Relationship of Physician Counseling to Weight Loss Among Patients With Nonalcoholic Fatty Liver Disease: An Observational Cohort Study Using National Health and Education Survey Data
Jessica P.E. Davis, Zachary H. Henry, Curtis K. Argo, Patrick G. Northup – 6 November 2019
Reply
Jiro Kusakabe, Shintaro Yagi, Shinji Uemoto – 6 November 2019
Anatomical Pitfall in Right Posterior Sector Graft Procurement in Living Donor Liver Transplantation
Ashwin Rammohan, Mettu S. Reddy, Mohamed Rela – 6 November 2019
Nutrition Priorities: Diet Recommendations in Liver Cirrhosis
Olivia Moss – 6 November 2019
AGA Clinical Practice Update on Surgical Risk Assessment and Perioperative Management in Cirrhosis: Expert Review
Patrick G. Northup, Lawrence S. Friedman, Patrick S. Kamath – 6 November 2019
Congenital Heart Disease and the Liver
Moira B. Hilscher, Patrick S. Kamath – 6 November 2019
Circulating MicroRNA‐122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD
Norio Akuta, Yusuke Kawamura, Yasuji Arase, Satoshi Saitoh, Shunichiro Fujiyama, Hitomi Sezaki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Yoshiyuki Suzuki, Fumitaka Suzuki, Kenji Ikeda, Hiromitsu Kumada – 5 November 2019 – The impact of circulating microRNA‐122 (miR‐122) on mortality in patients with histopathologically confirmed nonalcoholic fatty liver disease (NAFLD) remains unclear. We analyzed the overall survival rates in 441 Japanese patients with histopathologically confirmed NAFLD after a median follow‐up period of 4.7 years.